{
  "citations": [],
  "guideline": {
    "objCls": "Guideline Annotation",
    "id": "PA166273401",
    "name": "Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR",
    "alternateDrugAvailable": false,
    "cancerGenome": false,
    "crossReferences": [],
    "dosingInformation": false,
    "guidelineGenes": [],
    "hasTestingInfo": false,
    "history": [
      {
        "id": 1451889444,
        "date": "2022-09-22T14:18:20.767-07:00",
        "description": "fixed typo",
        "type": "Update",
        "version": 0
      }
    ],
    "literature": [],
    "pediatric": false,
    "recommendation": false,
    "relatedAlleles": [],
    "relatedChemicals": [
      {
        "objCls": "Chemical",
        "id": "PA448500",
        "name": "atorvastatin",
        "version": 21
      },
      {
        "objCls": "Chemical",
        "id": "PA449688",
        "name": "fluvastatin",
        "version": 21
      },
      {
        "objCls": "Chemical",
        "id": "PA450272",
        "name": "lovastatin",
        "version": 20
      },
      {
        "objCls": "Chemical",
        "id": "PA142650384",
        "name": "pitavastatin",
        "version": 3
      },
      {
        "objCls": "Chemical",
        "id": "PA451089",
        "name": "pravastatin",
        "version": 20
      },
      {
        "objCls": "Chemical",
        "id": "PA134308647",
        "name": "rosuvastatin",
        "version": 20
      },
      {
        "objCls": "Chemical",
        "id": "PA451363",
        "name": "simvastatin",
        "version": 23
      }
    ],
    "relatedGenes": [
      {
        "objCls": "Gene",
        "id": "PA130",
        "symbol": "CYP3A4",
        "name": "cytochrome P450 family 3 subfamily A member 4",
        "version": 8038
      },
      {
        "objCls": "Gene",
        "id": "PA131",
        "symbol": "CYP3A5",
        "name": "cytochrome P450 family 3 subfamily A member 5",
        "version": 7961
      },
      {
        "objCls": "Gene",
        "id": "PA189",
        "symbol": "HMGCR",
        "name": "3-hydroxy-3-methylglutaryl-CoA reductase",
        "version": 58
      }
    ],
    "source": "CPIC",
    "summaryMarkdown": {
      "id": 1451826380,
      "html": "<p>There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.</p>\n",
      "version": 0
    },
    "terms": [],
    "textMarkdown": {
      "id": 1451826381,
      "html": "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/\" target=\"_blank\">CPIC&reg; guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms</a>.</p>\n<h3 id=\"february-2022-update\">February 2022 Update</h3>\n<ul>\n<li>\n<p>The <a rel=\"noopener noreferrer\" href=\"https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.2557\" target=\"_blank\">CPIC guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms</a>, has been published in Clinical Pharmacology and Therapeutics. CPIC authors summarize literature supporting how SLCO1B1, ABCG2, and CYP2C9 genotype test results should be applied to optimize new or existing statin therapy to reduce the risk of statin-associated musculoskeletal symptoms (SAMS). The current document replaces the original 2012 guideline and the 2014 update for SLCO1B1 and simvastatin. New to this guideline are the addition of recommendations for CYP2C9 and ABCG2 and addition of recommendations for all statins. No recommendations are provided for statins and CYP3A4/5 and HMGCR due to weak evidence and the lack of conclusive clinical action based on genotype.</p>\n</li>\n<li>\n<p>This guideline is applicable to:</p>\n<ul>\n<li>adult patients</li>\n<li>pediatric patients</li>\n</ul>\n</li>\n<li>\n<p>Excerpt from the 2022 statin dosing guideline:</p>\n<ul>\n<li>&quot;We reviewed the evidence for SLCO1B1, ABCG2, CYP2C9, CYP3A4/5, and HMGCR, and applied a grading system for each piece of evidence that evaluated an association between genotype and phenotype (Tables S1-S5). We found the highest levels of evidence for SLCO1B1 (all statins), ABCG2 (rosuvastatin), and CYP2C9 (fluvastatin), and this evidence forms the basis for therapeutic recommendations in the current guideline. Evidence tables for CYP3A4/5 and HMGCR are provided in the supplement (Tables S4 and S5). Based on weak evidence and the lack of conclusive clinical action based on genotype, no recommendations are provided for statins and CYP3A4/5 and HMGCR.&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/statins/2022/publication.pdf\" target=\"_blank\">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/statins/2022/supplement.pdf\" target=\"_blank\">2022 supplement</a></li>\n</ul>\n</li>\n</ul>\n",
      "version": 2
    },
    "userId": "lgong",
    "version": 3
  }
}